IKT
NASDAQ
US
Inhibikase Therapeutics, Inc. - Common Stock
$1.80
▼ $-0.01
(-0.55%)
Vol 760K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$248.6M
ROE
-57.2%
Margin
-5981.3%
D/E
0.00
Beta
0.92
52W
$1–$3
Wall Street Consensus
12 analysts · Apr 20264
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
91.7%
Buy Rating
Price Chart
Similar Stocks
CHRS
Coherus Oncology Inc
P/E 1.1
$171.6M
ALXO
ALX Oncology Holdings Inc
$61.3M
TENX
Tenax Therapeutics Inc
$76.1M
KROS
Keros Therapeutics Inc
P/E 9.6
$620.3M
VYGR
Voyager Therapeutics Inc
$218.5M
RNA
Atrium Therapeutics Inc
$10.9B
ELDN
Eledon Pharmaceuticals Inc
$113.4M
CAMP
CAMP4 Therapeutics Corp
$318.0M
Earnings
Beat rate: 40.0%
Next Report
May 12, 2026
EPS Estimate: $-0.10
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.10 | — | — |
| Dec 2025 | $-0.10 | $-0.09 | +$0.01 |
| Sep 2025 | $-0.13 | $-0.13 | +$0.00 |
| Jun 2025 | $-0.09 | $-0.11 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$5.8M | -$12.1M | -$13.7M | -$9.9M | -$11.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -41.1% | -49.7% | -41.3% | -41.3% | -41.1% | -57.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -5981.2% | -5981.2% | -5981.2% | -5981.2% | -5981.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 10.09 | 11.01 | 10.11 | 10.11 | 10.09 | 11.73 |
Key Ratios
ROA (TTM)
-52.8%
P/S (TTM)
776.87
P/B
2.3
EPS (TTM)
$-1.15
CF/Share
$-3.92
52W High
$3.49
52W Low
$1.33
$1.33
52-Week Range
$3.49
Financial Health
Free Cash Flow
-$10.6M
Cash
$38.3M
Total Debt
$0
As of Sep 30, 2025
How does IKT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IKT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
776.9
▲
5946%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
2.3
▼
6%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IKT profitability vs Biotechnology peers
ROE
-57.2%
▲
15%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-5981.3%
▼
1986%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-52.8%
▼
13%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
IKT financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
11.7
▲
164%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.9
▼
5%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
IKT fundamentals radar
IKT
Peer median
Industry
IKT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IKT vs peers: key metrics
Top Holders
Top 5: 62.21%Sands Capital Alternatives,…
17.32%
$21.7M
Soleus Capital Management, …
14.47%
$18.1M
Fairmount Funds Management …
11.47%
$14.4M
Adar1 Capital Management, L…
10.73%
$13.4M
Trails Edge Capital Partner…
8.22%
$10.3M
As of Dec 31, 2025
Latest News
Downed U.S. Drone Appears On TikTok Live As Iraqi Children Try To …
ZeroHedge · Apr 04
‘Not quite Greggs’: TikTok creators put London’s ‘gentrified’ bakeries to the test
The Guardian · Apr 04
Influencer tax rules: A guide for TikTok, Twitch, and other creators
Yahoo Finance · Mar 25
M&A News: TikTok Owner ByteDance Sells Gaming Unit Moonton to Saudi Arabia …
Yahoo Finance · Mar 22